Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

That study showed the competitive inhibitory profile of chlortetracycline and the catalytic binding domain of EphB1 tyrosine kinase (transmembrane proteins that mediate communication between cells).

Characterized by two or more tandemly arranged kinase domains, these proteins confer resistance to a range of fungal pathogens, including stripe rust, leaf rust, stem rust, powdery mildew ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Like most signaling pathways, two-component systems are modular schemes built around a central mechanism involving conserved domains. The conserved kinase core of the HK catalyzes ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.